ARFGEF1

Across TCGA pan-cancer cohorts, ARFGEF1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ARFGEF1 data layer compared with 23 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ARFGEF1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ARFGEF1 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where ARFGEF1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	III,IV	0.630	0.939	.008	36	view →
LUAD	OS	Median	III,IV	1.000	0.770	.007	14	view →
PDAC	DFS	Quartile	All	0.306	0.534	.020	4	view →
LSCC	DFS	Quartile	II,III,IV	0.386	1.000	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ARFGEF1–CCRCC (OS)

Open the CCRCC breakdown →